Cydar Medical Announces a Strategic Collaboration with Medtronic

Cydar Medical today announced it has entered a strategic collaboration with Medtronic, a global leader in healthcare technology.

Cydar Medical notes under the pilot arrangement, Cydar’s EV Maps software will be introduced to up to 40 new global sites, combining Cydar’s augmented intelligence technology with Medtronic’s services and case support, with the goal of improving patient care.

The Cydar EV Maps software harnesses the latest in cloud GPU computing, computer vision and machine learning technology to advance surgical visualization and decision-making in theatre and across the care pathway. This enables clinicians to create detailed patient-specific 3D maps for procedure planning, image-guided navigation, and post-operative review, resulting in less radiation exposure to the patient and the clinical team, reduced procedure time, and increased delivery confidence.1-3 This pilot program will also inform the future development of predictive analytics to support procedure planning, by assessing factors such as the risk of endoleaks, sac regression probability and more.

Medtronic is the first medical technology company to enter a public strategic collaboration in digital endovascular technology to advance aortic patient treatment decisions. The collaboration is part of Medtronic’s ongoing commitment to innovation in aortic care for physicians and their patients.

“Medtronic aims to revolutionize endovascular aortic treatment with digital solutions with this phased approach. By collecting data across the patient journey—before, during and after procedure—our goal is to provide analytic support to make our endovascular stent grafts ‘smart’.” said Carolyn Sleeth, VP, General Manager, Aortic.

“By collaborating with Medtronic to bring our Cydar EV Maps solution to up to 40 new hospital sites, we are a step closer to achieving our mission to ensure every image-guided endovascular procedure goes exactly as planned,” said Paul Mussenden, CEO of Cydar.

Cydar EV Maps is currently available in the EU, UK and US. It is certified Software-as-a-Medical Device with an EU CE mark and U.S. FDA 510(k) clearance.

Cydar specializes in medical computer vision, machine learning and cloud high-performance computing. Cydar EV Maps is a cloud-based software platform that generates patient specific 3D Maps of soft tissue vasculature to support more effective image guided, minimally invasive endovascular surgery. The system comprises pre-operative procedure planning functionality and real time, AI enabled 3D intra-operative imaging and procedure guidance, with procedure video capture and post procedure review functions.

When guidewires and instruments deform blood vessel, the real-time imaging updates the Map to match the new, deformed patient anatomy. This results in an accurate 3D Map on the screen throughout a procedure. The Cydar EV Maps platform also allows post procedure outcome analysis. The result of this integration of procedure planning, guidance and review is that surgeons can work more accurately and efficiently – enabling an ~50%1 reduction in radiation exposure, a significant reduction in fluoroscopy time and reducing procedure times by more than 20%2 while helping achieve better outcomes for patients.

Cydar’s Surgical Augmented Intelligence technology is learning from every case to develop a deeper understanding of surgery. Headquartered in Cambridge, UK, Cydar’s focus is to build a future where all procedures proceed exactly as planned News about Cydar can be found at www.cydarmedical.com/news


References

References:

1 Maurel B, Martin‑Gonzalez T, Chong D, et al. A prospective observational trial of fusion imaging in infrarenal aneurysms. J Vasc Surg. 2018;68:1706‑1713.

2 Shortell C, VEITHsymposium New York, 2017

3 Cydar Medical data on file.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version